Apollo Hospitals (APOLLOHOSP) Q3 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 earnings summary
8 Jan, 2026Executive summary
Consolidated revenue grew 14% year-over-year in Q3 FY25, with EBITDA up 24% and PAT up 52%, reflecting robust growth across all business segments and a positive turnaround in digital health.
All core segments, including Healthcare Services, Diagnostics & Retail Health (AHLL), and Digital Health & Pharmacy Distribution (Apollo HealthCo), reported double-digit revenue growth.
Strategic focus on high-end specialties, digital innovation, and new facility investments drove revenue intensity and margin expansion.
Expansion initiatives include new hospital projects, digital health platform enhancements, and integration of Keimed for pharmacy distribution.
Interim dividend of Rs. 9 per share declared for FY25.
Financial highlights
Q3 FY25 consolidated revenue: INR 5,527 crore (Rs. 55,269 million), up 14% YoY; EBITDA: INR 762 crore (Rs. 7,615 million), up 24% YoY; PAT: INR 372 crore (Rs. 3,723 million), up 52% YoY.
YTD Dec FY25 consolidated revenue: Rs. 162,018 million, up 15% YoY; EBITDA: Rs. 22,521 million, up 29% YoY; PAT: Rs. 10,563 million, up 64% YoY.
Healthcare Services Q3 revenue: INR 2,785 crore (Rs. 27,850 million), up 13% YoY; EBITDA margin 24.1%; AHLL Q3 revenue: INR 390 crore (Rs. 3,895 million), up 15% YoY, EBITDA margin 8.8%; HealthCo Q3 revenue: INR 2,352 crore (Rs. 23,524 million), up 15% YoY, EBITDA margin 8.4%.
HealthCo PAT turned positive in Q3 FY25 (Rs. 321 million) vs. loss in Q3 FY24; AHLL EBITDA up 32% YoY.
Diluted EPS for Q3 FY25: Rs. 25.89; YTD Dec FY25: Rs. 73.46 (not annualized).
Outlook and guidance
Three new facilities to open in FY26 H2; Gurugram and Hyderabad to open by end of FY26, with quick break-even expected.
Targeting consolidated Year 3 revenues of ~INR 25,000 crore for the merged HealthCo-Keimed entity, with operating margins of 7–8%.
Expectation to achieve INR 250 bn revenue in FY27 at 22% annual CAGR, with 7–8% EBITDA margin.
Digital business targeting break-even by end of Q2 or Q3 FY26, with GMV breakeven at INR 900–1,000 crore.
On track to add 3,512 beds over 3–4 years starting FY26, supporting long-term growth.
Latest events from Apollo Hospitals
- Q1 FY27 revenue grew 21% YoY to INR 7,043 crores, with strong EBITDA and PAT growth across segments.APOLLOHOSP
Q1 26/27 - FY26 revenue up 16%, EBITDA up 25%, PAT up 34%, with major digital and hospital expansion.APOLLOHOSPQ4 25/26
- Q3 FY26 saw 17% revenue and 35% PAT growth, robust expansion, and a Rs.10 interim dividend.APOLLOHOSPQ3 25/26
- Q2 FY26 revenue up 13% YoY, EBITDA up 15%, PAT up 26%, with strong expansion and digital gains.APOLLOHOSPQ2 2026
- Q1 FY26 saw 15% revenue, 26% EBITDA, and 42% PAT growth, with strong digital momentum.APOLLOHOSPQ1 25/26
- Equity infusion and merger set to create India's top integrated pharmacy and digital health platform.APOLLOHOSPTransaction Rationale, Valuation and Governance Presentation
- Q2 FY25 delivered 15% revenue, 30% EBITDA, and 63% PAT growth, with major expansion underway.APOLLOHOSPQ2 24/25
- 15% revenue growth, 33% EBITDA rise, and 83% PAT surge, with major digital and pharmacy expansion.APOLLOHOSPQ1 24/25
- FY25 revenue up 14% YoY, PAT up 61%, with major expansion and INR 19/share dividend.APOLLOHOSPQ4 24/25